BioVentrix announced today that it completed a $48.5 million Series A financing round to support its treatment for heart failure. Mansfield, Massachusetts-based BioVentrix develops minimally invasive therapies. They treat the dilated left ventricle and reverse the left ventricular remodeling process in congestive heart failure. Andera Partners led the Series A funding round. Investors also included […]
BioVentrix
FDA expands access to BioVentrix ischemic heart failure treatment
BioVentrix announced today that it received FDA approval for its application for an expanded access program for the Revivent TC system. San Ramon, California-based BioVentrix designed the Revivent TC system to support a minimally invasive heart procedure. It treats a dilated left ventricle of patients with ischemic heart failure. They also have reduced ejection fraction […]
BioVentrix expands heart failure treatment portfolio with MateraCor acquisition
BioVentrix announced today that it has acquired MateraCor, a company developing injectable alginate-based hydrogel to treat heart failure. San Ramon, Calif.–based BioVentrix is a privately held medical device company focused on less invasive therapies to treat the left ventricle. The financial terms of the deal were not disclosed. “This is an exciting time for BioVentrix […]
BioVentrix appoints Jim Dillon president and CEO
BioVentrix today said it appointed Jim Dillon as president and CEO. The co-founder of Reprieve Cardiovascular, Dillon led its financing and development of a therapy for acute decompensated heart failure. He has also held a number of leadership roles at St. Jude Medical, Abiomed, TherOx and InfraReDx. “Jim’s field-based leadership style, combined with his proven […]
BioVentrix granted CE Mark extension for Revivent TC system
BioVentrix announced today that it received an extension of its CE Mark for the Revivent TC transcatheter ventricular enhancement system for heart failure. The extension of the initial CE Mark approval BioVentrix won in 2016 allows the device to be marketed throughout European Union member nations until May 2024, according to a news release. BioVentrix’s […]
BioVentrix wins breakthrough nod for transcatheter-based structural heart device
BioVentrix announced today that it won FDA breakthrough device designation for its Revivent TC transcatheter ventricular enhancement system for heart failure. The Revivent TC system is used in less invasive ventricular enhancement (LIVE) procedures intended to exclude scar tissue on the left ventricle that resulted from a heart attack so that the healthy portion of […]
BioVentrix launches trial for Revivent TC heart failure device
BioVentrix said today that it enrolled and treated the first patient in its Revive-HF European trial to evaluate the Revivent TC system for the treatment of ischemic cardiomyopathy-induced heart failure. The patient, who had suffered a heart attack that resulted in left ventricle scarring and ischemic heart failure, was successfully implanted with three anchor pairs […]
Dexcom adds COO to CFO Blackford’s title | Personnel Moves, September 19, 2019
Dexcom (NSDQ:DXCM) this week added the COO role to CFO Quentin Blackford’s title. Blackford is now in charge of Dexcom’s global supply chain, manufacturing operations and expansion into new markets, the San Diego-based company said. He’s been CFO of the continuous glucose monitor maker since 2017, when he left the chief finance spot at NuVasive (NSDQ:NUVA). […]
Bioventrix adds $18m
BioVentrix added some $18 million to the $21.8 million it raised earlier this year, according to a regulatory filing. The San Ramon, Calif.-based company said it pulled down a total of $40 million in the round from 162 unnamed investors, after reporting the earlier raise in April. The first sale was logged in August 2017, […]
BioVentrix raises $22m
BioVentrix has raised $21.8 million in a round of equity financing, according to a recently posed SEC filing. The company is looking to bring in an additional $18.2 million in the round, which would bring the total raised up to $40 million. A total of 158 unnamed investors joined the offering, with the first date […]
BioVentrix wins renewed German reimbursement for Revivent TC heart device
BioVentrix said today that it won renewed German reimbursement for its Revivent TC transcatheter ventricular enhancement system. The San Ramon, Calif.-based company said that the German Institute for Hospital Remuneration reconfirmed NUB 1 status for the Revivent TC device. NUB 1 status allows participating hospitals to receive full reimbursement for the product and supplemental payments for […]